Jing Li1, Jian Gu2. 1. College of Pharmacy, Southwest Minzu University, No. 16 South 4th Section, 1st Ring Road, Chengdu, Sichuan, 610041, People's Republic of China. 27918716@qq.com. 2. College of Pharmacy, Southwest Minzu University, No. 16 South 4th Section, 1st Ring Road, Chengdu, Sichuan, 610041, People's Republic of China.
Abstract
BACKGROUND AND OBJECTIVE: Use of the vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) has led to considerable improvements in the clinical outcome of patients with various tumor types. However, VEGFR-TKIs may be associated with increased incidence of cardiovascular toxicities. We conducted this meta-analysis to systematically review the risk of cardiovascular toxicities with VEGFR-TKIs in cancer patients. METHODS: The relevant studies of the randomized controlled trials in cancer patients treated with VEGFR-TKIs were retrieved and a systematic evaluation was conducted. EMBASE, MEDLINE, and PubMed were searched for articles published until April 2018. RESULTS: A total of 77 randomized controlled trials and 27,353 patients were included. The current meta-analysis suggests that the use of VEGFR-TKIs significantly increases the risk of developing cardiovascular toxicities, such as all-grade and high-grade hypertension, all-grade bleeding, and all-grade cardiac dysfunction. Hypertension was the most common cardiovascular toxicity. There was no significant increased risk of all-grade and high-grade thromboembolism, high-grade bleeding, and high-grade cardiac dysfunction associated with these agents. CONCLUSIONS: The available data suggest that the use of VEGFR-TKIs is associated with a significantly increased risk of cardiovascular toxicities in cancer patients. Clinicians should be aware of this risk and perform regular cardiovascular monitoring.
BACKGROUND AND OBJECTIVE: Use of the vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) has led to considerable improvements in the clinical outcome of patients with various tumor types. However, VEGFR-TKIs may be associated with increased incidence of cardiovascular toxicities. We conducted this meta-analysis to systematically review the risk of cardiovascular toxicities with VEGFR-TKIs in cancerpatients. METHODS: The relevant studies of the randomized controlled trials in cancerpatients treated with VEGFR-TKIs were retrieved and a systematic evaluation was conducted. EMBASE, MEDLINE, and PubMed were searched for articles published until April 2018. RESULTS: A total of 77 randomized controlled trials and 27,353 patients were included. The current meta-analysis suggests that the use of VEGFR-TKIs significantly increases the risk of developing cardiovascular toxicities, such as all-grade and high-grade hypertension, all-grade bleeding, and all-grade cardiac dysfunction. Hypertension was the most common cardiovascular toxicity. There was no significant increased risk of all-grade and high-grade thromboembolism, high-grade bleeding, and high-grade cardiac dysfunction associated with these agents. CONCLUSIONS: The available data suggest that the use of VEGFR-TKIs is associated with a significantly increased risk of cardiovascular toxicities in cancerpatients. Clinicians should be aware of this risk and perform regular cardiovascular monitoring.
Authors: Miguel Martin; Henri Roche; Tamas Pinter; John Crown; M John Kennedy; Louise Provencher; Frank Priou; Wolfgang Eiermann; Encarna Adrover; Istvan Lang; Manuel Ramos; Jean Latreille; Agnieszka Jagiełło-Gruszfeld; Tadeusz Pienkowski; Emilio Alba; Raymond Snyder; Sachin Almel; Janusz Rolski; Montserrat Munoz; Rebecca Moroose; Sara Hurvitz; Ana Baños; Henry Adewoye; Yong-Jiang Hei; Mary-Ann Lindsay; Matthieu Rupin; David Cabaribere; Yasmin Lemmerick; John R Mackey Journal: Lancet Oncol Date: 2011-03-21 Impact factor: 41.316
Authors: Susanne Krege; Heidrun Rexer; Frank vom Dorp; Patrick de Geeter; Theodor Klotz; Margitte Retz; Axel Heidenreich; Michael Kühn; Joern Kamradt; Susan Feyerabend; Christian Wülfing; Stefan Zastrow; Peter Albers; Oliver Hakenberg; Jan Roigas; Martin Fenner; Hans Heinzer; Mark Schrader Journal: BJU Int Date: 2014-03 Impact factor: 5.588
Authors: T Kato; K Muro; K Yamaguchi; H Bando; S Hazama; K Amagai; H Baba; T Denda; X Shi; K Fukase; J Skamoto; H Mishima Journal: Ann Oncol Date: 2011-08-09 Impact factor: 32.976
Authors: Eric Raymond; Laetitia Dahan; Jean-Luc Raoul; Yung-Jue Bang; Ivan Borbath; Catherine Lombard-Bohas; Juan Valle; Peter Metrakos; Denis Smith; Aaron Vinik; Jen-Shi Chen; Dieter Hörsch; Pascal Hammel; Bertram Wiedenmann; Eric Van Cutsem; Shem Patyna; Dongrui Ray Lu; Carolyn Blanckmeister; Richard Chao; Philippe Ruszniewski Journal: N Engl J Med Date: 2011-02-10 Impact factor: 91.245
Authors: Brian I Rini; Bohuslav Melichar; Takeshi Ueda; Viktor Grünwald; Mayer N Fishman; José A Arranz; Angel H Bair; Yazdi K Pithavala; Glen I Andrews; Dmitri Pavlov; Sinil Kim; Eric Jonasch Journal: Lancet Oncol Date: 2013-10-18 Impact factor: 41.316
Authors: Axel Grothey; Eric Van Cutsem; Alberto Sobrero; Salvatore Siena; Alfredo Falcone; Marc Ychou; Yves Humblet; Olivier Bouché; Laurent Mineur; Carlo Barone; Antoine Adenis; Josep Tabernero; Takayuki Yoshino; Heinz-Josef Lenz; Richard M Goldberg; Daniel J Sargent; Frank Cihon; Lisa Cupit; Andrea Wagner; Dirk Laurent Journal: Lancet Date: 2012-11-22 Impact factor: 79.321
Authors: Tracy T Batchelor; Paul Mulholland; Bart Neyns; L Burt Nabors; Mario Campone; Antje Wick; Warren Mason; Tom Mikkelsen; Surasak Phuphanich; Lynn S Ashby; John Degroot; Rao Gattamaneni; Lawrence Cher; Mark Rosenthal; Franz Payer; Juliane M Jürgensmeier; Rakesh K Jain; A Gregory Sorensen; John Xu; Qi Liu; Martin van den Bent Journal: J Clin Oncol Date: 2013-08-12 Impact factor: 44.544
Authors: Marina T Van Leeuwen; Steven Luu; Howard Gurney; Martin R Brown; Sallie-Anne Pearson; Kate Webber; Lee Hunt; Soojung Hong; Geoffrey P Delaney; Claire M Vajdic Journal: JNCI Cancer Spectr Date: 2020-08-24